The Cochaperone p23 Differentially Regulates Estrogen Receptor Target Genes and Promotes Tumor Cell Adhesion and Invasion

REFERENCES

• Bagatell, R., O. Khan, G. Paine-Murrieta, C. W. Taylor, S. Akinaga, and L. Whitesell. 2001. Destabilization of steroid receptors by heat shock protein 90-binding drugs: a ligand-independent approach to hormonal therapy of breast cancer. Clin. Cancer Res. 7:2076–2084.
   PubMedGoogle Scholar
• Beliakoff, J., R. Bagatell, G. Paine-Murrieta, C. W. Taylor, A. E. Lykkesfeldt, and L. Whitesell. 2003. Hormone-refractory breast cancer remains sensitive to the antitumor activity of heat shock protein 90 inhibitors. Clin. Cancer Res. 9:4961–4971.
   PubMed Web of Science ®Google Scholar
• Boxer, L. M., and C. V. Dang. 2001. Translocations involving c-myc and c-myc function. Oncogene 20:5595–5610.
   PubMed Web of Science ®Google Scholar
• Burrows, F., H. Zhang, and A. Kamal. 2004. Hsp90 activation and cell cycle regulation. Cell Cycle 3:1530–1536.
   PubMed Web of Science ®Google Scholar
• Chiosis, G., M. Vilenchik, J. Kim, and D. Solit. 2004. Hsp90: the vulnerable chaperone. Drug Discov. Today 9:881–888.
   PubMed Web of Science ®Google Scholar
• Dabrosin, C., A. C. Johansson, and K. Ollinger. 2004. Decreased secretion of Cathepsin D in breast cancer in vivo by tamoxifen: mediated by the mannose-6-phosphate/IGF-II receptor? Breast Cancer Res. Treat. 85:229–238.
   PubMedGoogle Scholar
• DeFranco, D. B., and P. Csermely. 2000. Steroid receptor and molecular chaperone encounters in the nucleus. Sci. STKE 2000:PE1.
   PubMedGoogle Scholar
• Dubik, D., and R. P. Shiu. 1992. Mechanism of estrogen activation of c-myc oncogene expression. Oncogene 7:1587–1594.
   PubMed Web of Science ®Google Scholar
• Eustace, B. K., T. Sakurai, J. K. Stewart, D. Yimlamai, C. Unger, C. Zehetmeier, B. Lain, C. Torella, S. W. Henning, G. Beste, B. T. Scroggins, L. Neckers, L. L. Ilag, and D. G. Jay. 2004. Functional proteomic screens reveal an essential extracellular role for hsp90 alpha in cancer cell invasiveness. Nat. Cell Biol. 6:507–514.
   PubMed Web of Science ®Google Scholar
• Felts, S. J., and D. O. Toft. 2003. p23, a simple protein with complex activities. Cell Stress Chaperones 8:108–113.
   PubMed Web of Science ®Google Scholar
• Fliss, A. E., S. Benzeno, J. Rao, and A. J. Caplan. 2000. Control of estrogen receptor ligand binding by Hsp90. J. Steroid Biochem. Mol. Biol. 72:223–230.
   PubMed Web of Science ®Google Scholar
• Freeman, B. C., and K. R. Yamamoto. 2002. Disassembly of transcriptional regulatory complexes by molecular chaperones. Science 296:2232–2235.
   PubMed Web of Science ®Google Scholar
• Graham, J. D., D. L. Bain, J. K. Richer, T. A. Jackson, L. Tung, and K. B. Horwitz. 2000. Nuclear receptor conformation, coregulators, and tamoxifen-resistant breast cancer. Steroids 65:579–584.
   PubMedGoogle Scholar
• Hall, J. M., D. P. McDonnell, and K. S. Korach. 2002. Allosteric regulation of estrogen receptor structure, function, and coactivator recruitment by different estrogen response elements. Mol. Endocrinol. 16:469–486.
   PubMed Web of Science ®Google Scholar
• Hanahan, D., and R. A. Weinberg. 2000. The hallmarks of cancer. Cell 100:57–70.
   PubMed Web of Science ®Google Scholar
• Ioachim, E., A. Charchanti, E. Briasoulis, V. Karavasilis, H. Tsanou, D. L. Arvanitis, N. J. Agnantis, and N. Pavlidis. 2002. Immunohistochemical expression of extracellular matrix components tenascin, fibronectin, collagen type IV and laminin in breast cancer: their prognostic value and role in tumour invasion and progression. Eur. J. Cancer 38:2362–2370.
   PubMed Web of Science ®Google Scholar
• Isaacs, J. S., W. Xu, and L. Neckers. 2003. Heat shock protein 90 as a molecular target for cancer therapeutics. Cancer Cell 3:213–217.
   PubMed Web of Science ®Google Scholar
• Jameel, A., R. A. Skilton, T. A. Campbell, S. K. Chander, R. C. Coombes, and Y. A. Luqmani. 1992. Clinical and biological significance of HSP89 alpha in human breast cancer. Int. J. Cancer 50:409–415.
   PubMed Web of Science ®Google Scholar
• Jordan, V. C. 1999. Estrogen receptor as a target for the prevention of breast cancer. J. Lab. Clin. Med. 133:408–414.
   PubMedGoogle Scholar
• Kamal, A., L. Thao, J. Sensintaffar, L. Zhang, M. F. Boehm, L. C. Fritz, and F. J. Burrows. 2003. A high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors. Nature 425:407–410.
   PubMed Web of Science ®Google Scholar
• Kaplan, R. N., R. D. Riba, S. Zacharoulis, A. H. Bramley, L. Vincent, C. Costa, D. D. MacDonald, D. K. Jin, K. Shido, S. A. Kerns, Z. Zhu, D. Hicklin, Y. Wu, J. L. Port, N. Altorki, E. R. Port, D. Ruggero, S. V. Shmelkov, K. K. Jensen, S. Rafii, and D. Lyden. 2005. VEGFR1-positive hematopoietic bone marrow progenitors initiate the pre-metastatic niche. Nature 438:820–827.
   PubMed Web of Science ®Google Scholar
• Knoblauch, R., and M. J. Garabedian. 1999. Role for Hsp90-associated cochaperone p23 in estrogen receptor signal transduction. Mol. Cell. Biol. 19:3748–3759.
   PubMedGoogle Scholar
• Krebs, J., P. Saremaslani, and R. Caduff. 2002. ALG-2: a Ca2+-binding modulator protein involved in cell proliferation and in cell death. Biochim. Biophys. Acta 1600:68–73.
   PubMed Web of Science ®Google Scholar
• Kushner, P. J., D. A. Agard, G. L. Greene, T. S. Scanlan, A. K. Shiau, R. M. Uht, and P. Webb. 2000. Estrogen receptor pathways to AP-1. J. Steroid Biochem. Mol. Biol. 74:311–317.
   PubMed Web of Science ®Google Scholar
• McLaughlin, S. H., F. Sobott, Z. P. Yao, W. Zhang, P. R. Nielsen, J. G. Grossmann, E. D. Laue, C. V. Robinson, and S. E. Jackson. 2006. The co-chaperone p23 arrests the Hsp90 ATPase cycle to trap client proteins. J. Mol. Biol. 356:746–758.
   PubMed Web of Science ®Google Scholar
• Mileo, A. M., M. Fanuele, F. Battaglia, G. Scambia, P. Benedetti-Panici, S. Mancuso, and U. Ferrini. 1990. Selective overexpression of mRNA coding for 90 kDa stress-protein in human ovarian cancer. Anticancer Res. 10:903–906.
   PubMedGoogle Scholar
• Mollerup, J., T. N. Krogh, P. F. Nielsen, and M. W. Berchtold. 2003. Properties of the co-chaperone protein p23 erroneously attributed to ALG-2 (apoptosis-linked gene 2). FEBS Lett. 555:478–482.
   PubMedGoogle Scholar
• Oxelmark, E., R. Knoblauch, S. Arnal, L. F. Su, M. Schapira, and M. J. Garabedian. 2003. Genetic dissection of p23, an Hsp90 cochaperone, reveals a distinct surface involved in estrogen receptor signaling. J. Biol. Chem. 278:36547–36555.
   PubMedGoogle Scholar
• Platet, N., S. Cunat, D. Chalbos, H. Rochefort, and M. Garcia. 2000. Unliganded and liganded estrogen receptors protect against cancer invasion via different mechanisms. Mol. Endocrinol. 14:999–1009.
   PubMedGoogle Scholar
• Prest, S. J., F. E. May, and B. R. Westley. 2002. The estrogen-regulated protein, TFF1, stimulates migration of human breast cancer cells. FASEB J. 16:592–594.
   PubMedGoogle Scholar
• Shang, Y., X. Hu, J. DiRenzo, M. A. Lazar, and M. Brown. 2000. Cofactor dynamics and sufficiency in estrogen receptor-regulated transcription. Cell 103:843–852.
   PubMed Web of Science ®Google Scholar
• Stavreva, D. A., W. G. Muller, G. L. Hager, C. L. Smith, and J. G. McNally. 2004. Rapid glucocorticoid receptor exchange at a promoter is coupled to transcription and regulated by chaperones and proteasomes. Mol. Cell. Biol. 24:2682–2697.
   PubMed Web of Science ®Google Scholar
• Su, L. F., R. Knoblauch, and M. J. Garabedian. 2001. Rho GTPases as modulators of the estrogen receptor transcriptional response. J. Biol. Chem. 276:3231–3237.
   PubMedGoogle Scholar
• Trikha, M., Y. A. De Clerck, and F. S. Markland. 1994. Contortrostatin, a snake venom disintegrin, inhibits beta 1 integrin-mediated human metastatic melanoma cell adhesion and blocks experimental metastasis. Cancer Res. 54:4993–4998.
   PubMed Web of Science ®Google Scholar
• Watson, P. H., R. T. Pon, and R. P. Shiu. 1991. Inhibition of c-myc expression by phosphorothioate antisense oligonucleotide identifies a critical role for c-myc in the growth of human breast cancer. Cancer Res. 51:3996–4000.
   PubMed Web of Science ®Google Scholar
• Workman, P. 2003. Auditing the pharmacological accounts for Hsp90 molecular chaperone inhibitors: unfolding the relationship between pharmacokinetics and pharmacodynamics. Mol. Cancer Ther. 2:131–138.
   PubMed Web of Science ®Google Scholar